Drug Profile
Shigella sonnei vaccine - GlaxoSmithKline
Alternative Names: 1790GAHB vaccine; GSK-3536852A; GSK-3902986A; GVGH Shigella sonnei 1790GAHB vaccineLatest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Novartis
- Developer GlaxoSmithKline
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Shigella infections
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Shigella-infections(Prevention) in France (IM, Injection)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Shigella-infections(Prevention) in United Kingdom (IM, Injection)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Shigella-infections(Prevention) in United Kingdom (Intradermal)